Clinical ResearchCoronary Disease RiskMeta-Analysis of the Relationship Between Non–High-Density Lipoprotein Cholesterol Reduction and Coronary Heart Disease Risk
Coronary Disease Risk
Under an Elsevier user license
open archive
Key Words
non–HDL-cholesterol
coronary heart disease
meta-analysis
statins
fibrates
niacin
Abbreviations and Acronyms
CHD
coronary heart disease
CI
confidence interval
HDL-C
high-density lipoprotein cholesterol
LDL-C
low-density lipoprotein cholesterol
Cited by (0)
Dr. Robinson has received research grants from Abbott, Aegerion, AstraZeneca, Bristol-Myers Squibb, Daiichi-Sankyo, Hoffman La Roche, Merck, Merck Schering-Plough, and Takeda; has received speaker honoraria from Merck Schering-Plough; and has served as a consultant for AstraZeneca and Merck Schering-Plough. Dr. Jacobson has served as a consultant for Abbott, AstraZeneca, GlaxoSmithKline, Merck, Merck Schering-Plough, Pfizer, Reliant, and Sanofi-Aventis. Dr. Robinson had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Copyright © 2009 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.